CD274 and hepatocellular carcinoma: Recent phase 1/2 evaluations of nivolumab in HCC patients, 25 % of whom were chronic HBV patients, showed a 19 % objective response rate [36], suggesting that in the field of HBV, therapeutic blockade of PD1:PD-L1 will likely be employed first in those with HCC.